Acute CV Complications of Hematopoietic Stem Cell Transplantation

Quick Takes

  • Cardiovascular risk factors, prior exposure to cardiotoxic agents, and high-dose chemotherapy administered during hematopoietic stem cell transplantation (HSCT) conditioning contribute synergistically to post-HSCT cardiovascular complications.
  • Reduced intensity conditioning regimens associated with less cardiotoxicity are being used more frequently, particularly in older patients.

Introduction
HSCT is a potentially curative treatment for many malignancies, hemoglobinopathies, metabolic diseases, bone marrow failure syndromes, and primary immune deficiencies.1-3 In brief, HSCT accomplishes disease eradication through high-dose chemotherapy with or without radiation, leading to ablation of a patient's bone marrow, known as conditioning, followed by transplantation of either donor-derived stem cells (allogeneic HSCT), or patient-derived stem cells collected prior to conditioning (autologous HSCT). Complications can affect multiple organ systems and are results of the cytotoxic effects of the conditioning regimen, resulting cytopenias, and graft-versus-host disease in patients undergoing allogeneic HSCT. Cardiovascular complications of HSCT such as cardiomyopathy, arrhythmias, pulmonary hypertension, and pericardial effusions are increasingly recognized.4

Mechanisms of Cardiotoxicity in HSCT
Pre-HSCT cardiotoxic exposures (e.g., prior therapeutic exposure) and pre-existing cardiovascular disease are significant contributors to post-HSCT cardiovascular morbidity. In addition, cardiac adverse events have been attributed to different components of HSCT itself such as total body radiation ablative therapy combined with a multi-drug conditioning regimen, with many of the drugs employed associated with cardiovascular toxicity: cyclophosphamide,5 cytarabine,6 carmustine,7 and melphalan.8 Further, the dimethylsulfoxide used to preserve stem cells may also contribute to cardiac events (Table 1).9 This includes pulmonary hypertension, vascular disease, hypertension, cardiometabolic effects, arrhythmia, myocardial ischemia, and prolongation of the QT interval.10-13 Cardiovascular complications may also arise as consequences of other HSCT-related comorbidities such as sepsis,14 graft-versus-host disease,15-17 thrombotic microangiopathy,18,19 and hepatic veno-occlusive disease.20

Table 1: Causality and Mechanisms of Acute Cardiac Complications of HSCT*

Therapeutics Associated Cardiovascular Complications
Total body irradiation21,22 Pericarditis, congestive heart failure
Calcineurin inhibitors23 Hypertension
Cyclophosphamide5,24-28 Congestive heart failure, hemorrhagic myocarditis, pericarditis
Cytarabine6,29 Dysrhythmia, congestive heart failure, pericarditis
Carmustine7 Myocardial ischemia
Melphalan8,30 Dysrhythmia, congestive heart failure
Dimethylsulfoxide9 Bradycardia, cardiac arrest
Alemtuzumab (anti-CD52 antibody)31 Congestive heart failure, dysrhythmia, tachycardia
Vinca alkaloids29 Dysautonomia
Common Transplant Complications Associated Cardiovascular Complications
Graft-versus-host disease15-17,32 Pericardial effusion, bradycardia, dysrhythmia, coronary artery
disease, cardiomyolysis
Thrombotic microangiopathy17-19 Systemic hypertension, pulmonary hypertension, pericardial effusion
Sepsis14 Systolic dysfunction/myocardial depression, tachyarrhythmias
Hepatic veno-occlusive disease20 Fluid overload leading to decompensated heart failure
*Other drugs used to treat complications of HSCT may also have cardiac toxicity (e.g., certain antibiotics) but are not listed here. Additionally, other HSCT complications not included may exacerbate known cardiac disease (e.g., pulmonary complications leading to right heart dysfunction).

Risks of Short-Term Cardiotoxicity During HSCT
Adult Recipients
Myriad short-term cardiovascular complications may occur during or in the short term after HSCT.4 One challenge in determining the incidence of cardiac complications is the lack of standardized diagnostic criteria or surveillance techniques and heterogeneous populations. Overall, severe cardiac complications are generally rare. A retrospective study of 2,821 patients (median age 22, 58% male) status post-HSCT (55% autologous) between 1977 and 1997 identified 26 patients (0.9%, 19 adults and 7 children) who experienced major or lethal cardiotoxicity in the first 100 days post-HSCT. This included death from a cardiovascular cause, congestive heart failure requiring inotropic support, cardiac tamponade, or significant electrocardiographic abnormalities.31,33 These findings are difficult to extrapolate to other populations, notably older patients with increased incidence of cardiovascular risk factors and less cardiovascular reserve who represent a growing segment of the HSCT-eligible population as the population ages and use of the therapy is more common.

Arrhythmias occur commonly in the HSCT setting. Estimates of incidence ranges between 2% and 10% of adult recipients.34-41 Atrial fibrillation and flutter are the most frequently described arrhythmias, with supraventricular tachycardia occurring in up to 5.1% of patients.35,38-41 Although lethal arrhythmias are rare, the occurrence of arrhythmias has been associated with in-hospital and 1-year mortality.36,42

Congestive heart failure is generally considered a long-term complication of HSCT,43,44 but new onset left ventricular dysfunction or exacerbations of pre-existing congestive heart failure can also occur in the short term. New onset heart failure occurs in approximately 0.4-2.2% of recipients.21,34,37,45 However, inclusion criteria (e.g., presence of pre-HSCT cardiomyopathy), diagnostic criteria (echocardiographic screen versus clinically diagnosed decompensated heart failure), and duration of follow-up can differ significantly between centers or studies, leading in some cases to reported incidence of upwards of 20%.46

Beyond arrhythmia, ventricular dysfunction, and symptomatic heart failure, other cardiovascular disease can occur peri-HSCT, although less frequently. Myocardial infarction and severe pericardial effusion/tamponade also may occur during the course of HSCT and immediately after, though in general these are rare events.21,33,34

Pediatric Recipients
Although cardiac disease is an important cause of early post-HSCT morbidity, data regarding the frequency of acute cardiac complications in this population are limited compared with data for adult patients.4,47 In a prospective evaluation screening program of 227 pediatric patients undergoing HSCT at a single center, 32% of patients developed a new abnormality by echocardiogram in the first 100 days post-transplantation. Findings included new left ventricular systolic dysfunction in 6%, pericardial effusion in 27%, and elevated right ventricular pressure (>35% systemic pressure) in 9%.48 Whether these findings lead to clinically important disease is not well appreciated. Pulmonary hypertension is a potentially fatal complication of HSCT and often presents nonspecifically in children and young adults undergoing HSCT.18 Echocardiographic abnormalities are particularly common in pediatric patients who become critically ill after HSCT, and a team-based screening approach involving providers from bone marrow transplantation, cardiology, and intensive care can allow for early detection and timely intervention.49 Pericardial effusions occur for a number of reasons post-HSCT,17,22,48,50,51 and approximately 3-4% of pediatric patients will require pericardial drain placement in the first 100 days after HSCT.17,48

Pre-HSCT Evaluation
The perceived risks of HSCT-related cardiotoxicity have led to the incorporation of a cardiovascular evaluation in the pre-transplant assessment of HSCT. Although practice varies across centers, patients with a pre-transplant left ventricular ejection fraction of less than 35% are often denied HSCT. The data surrounding the association between pre-transplant ejection fraction and short-term outcomes do not support this practice.4 When cardiovascular complications arise after HSCT, their management is dependent on the status of the patient, the predicted outcome, and other cardiovascular comorbidities.

Conclusion
Cardiac complications may occur in both pediatric and adult patients after HSCT. Pre-HSCT cardiac comorbidities are common, particularly in adults. Pediatric patients undergoing HSCT for certain genetic conditions are at risk for idiosyncratic cardiac events during transplantation (e.g., beta thalassemia, Hurler syndrome). Even in patients undergoing HSCT with no known cardiac disease, use of radiation and anthracycline chemotherapy as part of pre-HSCT malignancy treatment may predispose to events occurring during and after HSCT. Cardiac disease, unless very severe, should not be a specific barrier to utilizing HSCT and can often be managed with a multidisciplinary team. However, to establish specific practice guidelines, further research and/or expert opinion statements are needed to standardize the approach to evaluating and managing cardiovascular disease associated with HSCT.

References

  1. D'Souza A, Lee S, Zhu X, Pasquini M. Current Use and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant 2017;23:1417-21.
  2. Rotz SJ, O'Riordan MA, Kim C, de Lima M, Gladwin MT, Little JA. Traffic Light: prognosis-based eligibility for clinical trials of hematopoietic SCT in adults with sickle cell anemia. Bone Marrow Transplant 2015;50:918-23.
  3. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813-26.
  4. Rotz SJ, Ryan TD, Hayek SS. Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation. J Thromb Thrombolysis 2020;Nov 24:[Epub ahead of print].
  5. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986;68:1114-8.
  6. Vaickus L, Letendre L. Pericarditis induced by high-dose cytarabine therapy. Arch Intern Med 1984;144:1868-9.
  7. Kanj SS, Sharara AI, Shpall EJ, Jones RB, Peters WP. Myocardial ischemia associated with high-dose carmustine infusion. Cancer 1991;68:1910-2.
  8. Olivieri A, Corvatta L, Montanari M, et al. Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Bone Marrow Transplant 1998;21:1049-53.
  9. Cox MA, Kastrup J, Hrubiško M. Historical perspectives and the future of adverse reactions associated with haemopoietic stem cells cryopreserved with dimethyl sulfoxide. Cell Tissue Bank 2012;13:203-15.
  10. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. J Am Coll Cardiol 2017;70:2552-65.
  11. Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol 2017;70:2536-51.
  12. Moslehi JJ. Cardiovascular Toxic Effects of Targeted Cancer Therapies. N Engl J Med 2016;375:1457-67.
  13. Tuzovic M, Mead M, Young PA, Schiller G, Yang EH. Cardiac Complications in the Adult Bone Marrow Transplant Patient. Curr Oncol Rep 2019;21:28.
  14. Ghafoor S, James M, Goldberg J, McArthur JA. Cardiac Dysfunction in Hematology Oncology and Hematopoietic Cell Transplant Patients. In: Duncan CN, Talano JAM, McArthur JA, eds. Critical Care of the Pediatric Immunocompromised Hematology/Oncology Patient: An Evidence-Based Guide. Springer International Publishing; 2019: 211-35.
  15. Vetrugno L, Tomasino S, Battezzi A, Parisella L, Bernardinetti M, Bove T. Cardiac tamponade and graft versus host disease: one more reason to remember. Tumori 2018;104:NP14-NP16.
  16. Ferreira DC, de Oliveira JS, Parísio K, Ramalho FMM. Pericardial effusion and cardiac tamponade: clinical manifestation of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter 2014;36:159-61.
  17. Pfeiffer TM, Rotz SJ, Ryan TD, et al. Pericardial effusion requiring surgical intervention after stem cell transplantation: a case series. Bone Marrow Transplant 2017;52:630-3.
  18. Dandoy CE, Hirsch R, Chima R, Davies SM, Jodele S. Pulmonary hypertension after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19:1546-56.
  19. Jodele S, Dandoy CE, Myers KC, et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transfus Apher Sci 2016;54:181-90.
  20. Ovchinsky N, Frazier W, Auletta JJ, et al. Consensus Report by the Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees on Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents, Part 3: Focus on Cardiorespiratory Dysfunction, Infections, Liver Dysfunction, and Delirium. Biol Blood Marrow Transplant 2018;24:207-18.
  21. Murdych T, Weisdorf DJ. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997. Bone Marrow Transplant 2001;28:283-7.
  22. Rhodes M, Lautz T, Kavanaugh-Mchugh A, et al. Pericardial effusion and cardiac tamponade in pediatric stem cell transplant recipients. Bone Marrow Transplant 2005;36:139-44.
  23. Hoorn EJ, Walsh SB, McCormick JA, Zietse R, Unwin RJ, Ellison DH. Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol 2012;25:269-75.
  24. Nishikawa T, Miyahara E, Kurauchi K, et al. Mechanisms of Fatal Cardiotoxicity following High-Dose Cyclophosphamide Therapy and a Method for Its Prevention. PLoS One 2015;10:e0131394.
  25. Martin M, Fornecker LM, Marcellin L, et al. Acute and fatal cardiotoxicity following high-dose cyclophosphamide in a patient undergoing autologous stem cell transplantation for systemic sclerosis despite satisfactory cardiopulmonary screening. Bone Marrow Transplant 2017;52:1674-7.
  26. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981;141:758-63.
  27. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992;10:995-1000.
  28. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991;9:1215-23.
  29. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther 2006;6:1249-69.
  30. Van Besien K, Devine S, Wickrema A, et al. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant 2003;32:471-6.
  31. Oshima K, Sakata-Yanagimoto M, Asano-Mori Y, et al. Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab. Bone Marrow Transplant 2005;36:821-4.
  32. Rackley C, Schultz KR, Goldman FD, et al. Cardiac manifestations of graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:773-80.
  33. Sakata-Yanagimoto M, Kanda Y, Nakagawa M, et al. Predictors for severe cardiac complications after hematopoietic stem cell transplantation. Bone Marrow Transplant 2004;33:1043-7.
  34. Alblooshi R, Kanfar S, Lord B, et al. Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. Eur J Haematol 2021;106:32-39.
  35. Chiengthong K, Lertjitbanjong P, Thongprayoon C, et al. Arrhythmias in hematopoietic stem cell transplantation: A systematic review and meta-analysis. Eur J Haematol 2019;103:564-72.
  36. Tonorezos ES, Stillwell EE, Calloway JJ, et al. Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow Transplant 2015;50:1212-6.
  37. Gul Z, Bashir Q, Cremer M, et al. Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. Leuk Lymphoma 2015;56:533-5.
  38. Singla A, Hogan WJ, Ansell SM, et al. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2013;19:1233-7.
  39. Steuter JA, Villanueva MLH, Loberiza FR, et al. Factors affecting the development of atrial fibrillation and atrial flutter (AF/AFL) following autologous hematopoietic SCT (auto-HSCT). Bone Marrow Transplant 2013;48:963-5.
  40. Feliz V, Saiyad S, Ramarao SM, Khan H, Leonelli F, Guglin M. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol 2011;34:356-9.
  41. Peres E, Levine JE, Khaled YA, et al. Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation. Bone Marrow Transplant 2010;45:149-52.
  42. Goldberg SL, Klumpp TR, Magdalinski AJ, Mangan KF. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol 1998;16:3796-802.
  43. Armenian SH, Sun CL, Shannon T, et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood 2011;118:6023-9.
  44. Armenian SH, Sun CL, Francisco L, et al. Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol 2008;26:5537-43.
  45. Mo XD, Xu LP, Liu DH, et al. Heart failure after allogeneic hematopoietic stem cell transplantation. Int J Cardiol 2013;167:2502-6.
  46. Lin CJ, Vader JM, Slade M, DiPersio JF, Westervelt P, Romee R. Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation. Cancer 2017;123:1800-9.
  47. Garaventa A, Porta F, Rondelli R, et al. Early deaths in children after BMT. Bone Marrow Transplantation Group of the Italian Association for Pediatric Hematology and Oncology (AIEOP) and Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Bone Marrow Transplant 1992;10:419-23.
  48. Rotz SJ, Ryan TD, Jodele S, et al. The injured heart: early cardiac effects of hematopoietic stem cell transplantation in children and young adults. Bone Marrow Transplant 2017;52:1171-9.
  49. Dandoy CE, Jodele S, Paff Z, et al. Team-based approach to identify cardiac toxicity in critically ill hematopoietic stem cell transplant recipients. Pediatr Blood Cancer 2017;64:e26513.
  50. Aldoss O, Gruenstein DH, Bass JL, et al. Pericardial effusion after pediatric hematopoietic cell transplant. Pediatr Transplant 2013;17:294-9.
  51. Neier M, Jin Z, Kleinman C, et al. Pericardial effusion post-SCT in pediatric recipients with signs and/or symptoms of cardiac disease. Bone Marrow Transplant 2011;46:529-38.

Clinical Topics: Arrhythmias and Clinical EP, Cardio-Oncology, Heart Failure and Cardiomyopathies, Noninvasive Imaging, Pericardial Disease, Pulmonary Hypertension and Venous Thromboembolism, Implantable Devices, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Statins, Acute Heart Failure, Pulmonary Hypertension, Echocardiography/Ultrasound

Keywords: Stroke Volume, Cardiovascular Diseases, Retrospective Studies, Pericardial Effusion, Anthracyclines, Cardiotoxicity, Bone Marrow Transplantation, Atrial Fibrillation, Cardiac Tamponade, Hypertension, Pulmonary, Critical Illness, Mucopolysaccharidosis I, beta-Thalassemia, Expert Testimony, Prospective Studies, Ventricular Pressure, Ventricular Function, Left, Risk Factors, Heart Failure, Ventricular Dysfunction, Left, Echocardiography, Myocardial Infarction, Cardiomyopathies, Neoplasms, Tachycardia, Supraventricular, Critical Care, Hematopoietic Stem Cell Transplantation, Hospitals, Patient Care Team, Melphalan, Carmustine, Dimethyl Sulfoxide, Graft vs Host Disease, Hepatic Veno-Occlusive Disease, Bone Marrow, Cytarabine, Transplantation Conditioning, Whole-Body Irradiation, Anemia, Myocardial Ischemia, Cyclophosphamide, Thrombotic Microangiopathies, Arrhythmias, Cardiac, Metabolic Diseases, Hemoglobinopathies, Pharmaceutical Preparations, Sepsis, Disease Eradication


< Back to Listings